Involvement of the Src-cortactin pathway in migration induced by IGF-1 and EGF in human breast cancer cells

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2128-2138

  Mezi, Silvia ^a   Todi, Laura ^a   Orsi, Errico ^b   Angeloni, Antonio ^c   Mancini, Patrizia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Actin cytoskeleton; Cell migration; Cortactin; Epidermal growth factor; Insulin like growth factor 1; Src

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; CORTACTIN; EPIDERMAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN C;

ACTIN FILAMENT; ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL ACTIVATION; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STIMULATION;

ACTINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CORTACTIN; EPIDERMAL GROWTH FACTOR; FEMALE; FOCAL ADHESIONS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MCF-7 CELLS; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TYROSINE;

EID: 84869798067     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1642     Document Type: Article

References (61)

1. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE and Hall DM: Molecular interactions in cancer cell metastasis. Acta Histochem 112: 3-25, 2010.
2. Bahr C and Groner B: The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 23: 1-14, 2005. (Pubitemid 41656866)
3. Wu H, Reynolds AB, Kanner SB, Vines RR and Parsons JT: Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol Cell Biol 11: 5113-5124, 1991. (Pubitemid 21895272)
4. Wu H and Parsons JT: Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 120: 1417-1426, 1993. (Pubitemid 23081688)
5. Weed SA and Parsons JT: Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 20: 6418-6434, 2001. (Pubitemid 32977848)
6. Daly RJ: Cortactin signalling and dynamic actin networks. Biochem J 382: 13-25, 2004.
7. Schuuring E, Verhoeven E, Litvinov S and Michalides RJ: The product of the EMS1 gene, amplified and overexpressed in human carcinoma, is homologous to a v-src substrate and is located in cell-substratum contact sites. Mol Cell Biol 13: 2891-2898, 1993. (Pubitemid 23133960)
8. Ormandy CJ, Musgrove EA, Hui R, Daly RJ and Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78: 323-335, 2003. (Pubitemid 36543212)
9. Head JA, Jiang D, Li M, Zorn LJ, Schaefer EM, Parsons JT and Weed SA: Cortactin tyrosine phosphorylation requires Rac1 activity and association with the cortical actin cytoskeleton. Mol Biol Cell 14: 3216-3229, 2003. (Pubitemid 37013122)
10. Rosenzweig SA and Atreya HS: Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80: 1115-1124, 2010.
11. Surmacz E: Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5: 95-105, 2000.
12. Baserga R: The IGF-I receptor in cancer research. Exp Cell Res 253: 1-6, 1999.
13. Jackson JG, White MF and Yee D: Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 273: 9994-10003, 1998. (Pubitemid 28183101)
14. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J and Mayer D: Downregulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89: 506-513, 2000.
15. Peyrat JP, Bonneterre J, Dusanter-Fourt I, Leroy-Martin B, Dijane J and Demaille A: Characterization of insulin-like growth factor 1 receptors (IGF-IR) in human breast cancer cell lines. Bull Cancer 76: 311-309, 1989.
16. Sepp-Lorenzino L, Rosen N and Lebwohl DE: Insulin and insulin-like growth factor signaling are defective in the MDA-MB-468 human breast cancer cell line. Cell Growth Differ 5: 1077-1083, 1994. (Pubitemid 24312283)
17. Jackson JG and Yee D: IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. Growth Horm IGF Res 9: 280-289, 1999. (Pubitemid 29524850)
18. Godden J, Leake R and Kerr DJ: The response of breast cancer cells to steroid and peptide growth factors. Anticancer Res 12: 1683-1688, 1992.
19. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion and metastasis of breast cancer. Cancer Res 58: 3353-3361, 1998. (Pubitemid 28371076)
20. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC and Osborne CK: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Investig 84: 1418-1423, 1989. (Pubitemid 19272227)
21. Doerr ME and Jones Jl: The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 271: 2443-2447, 1996.
22. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
23. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 4: 31-39, 2002.
24. Davidson NE, Gelmann EP, Lippman ME and Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223, 1987.
25. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD and Park JW: Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63: 3154-3161, 2003. (Pubitemid 36735867)
26. Callahan R and Hurvitz S: Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 23: 37-43, 2011.
27. Fillmore CM and Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25, 2008.
28. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D and Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284, 2006.
29. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68, 2010.
30. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L and Courtneidge SA: SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20: 9018-9027, 2000. (Pubitemid 32245931)
31. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS and Brandt BH: Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 16: 1823-1825, 2002.
32. Hirsch DS, Shen Y and Wu WJ: Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res 66: 3523-3530, 2006.
33. Playford MP and Schaller MD: The interplay between Src and integrins in normal and tumor biology. Oncogene 23: 7928-7946, 2004. (Pubitemid 39468852)
34. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT and Horwitz AR: Cell migration: integrating signals from front to back. Science 302: 1704-1709, 2003. (Pubitemid 37505725)
35. Azios NG and Dharmawardhane SF: Resveratrol and estradiol exert disparate effects on cell migration, call surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 7: 128-140, 2005. (Pubitemid 40315990)
36. Campbell DH, deFazio A, Sutherland RL and Daly RJ: Expression and tyrosine phoshorylation of EMS1 in human breast cancer cell lines. Int J Cancer 68: 485-492, 1996. (Pubitemid 26414504)
37. Ceccarelli S, Cardinali G, Aspite N, Picardo M, Marchese C, Torrisi MR and Mancini P: Cortactin involvement in the keratinocyte growth factor and fibroblast growth factor 10 promotion of migration and cortical actin assembly in human keratinocytes. Exp Cell Res 313: 1758-1777, 2007. (Pubitemid 46653878)
38. Huang C, Liu J, Haudenschild CC and Zhan X: The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem 273: 25770-25776, 1998. (Pubitemid 28475803)
39. Weed SA, Du Y and Parsons JT: Translocation of cortactin to the cell periphery is mediated by the small GTPase Rac1. J Cell Sci 111: 2433-2443, 1998. (Pubitemid 28434929)
40. Ren G, Helwani FM, Verma S, McLachlan RW, Weed SA and Yap AS: Cortactin is a functional target of E-cadherin-activated Src family kinases in MCF7 epithelial monolayers. J Biol Chem 284: 18913-18922, 2009.
41. Brown MC and Turner CE: Paxillin: adapting to change. Physiol Rev 84: 1315-1339, 2004. (Pubitemid 39287952)
42. Vincent AM and Feldman EL: Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 12: 193-197, 2002. (Pubitemid 35230190)
43. Biscardi JS, Tice DA and Parsons SJ: c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 76: 61-119, 1999. (Pubitemid 29190881)
44. Ravichandran KS: Signaling via Shc family adapter proteins. Oncogene 20: 6322-30, 2001.
45. Bae SN, Arand G, Azzam H, Pavasant P, Torri J, Frandsen TL and Thompson EW: Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in matrigel-based in vitro assays. Breast Cancer Res Treat 24: 241-255, 1993.
46. Jackson JG, Zhang X, Yoneda T and Yee D: Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 20: 7318-7325, 2001. (Pubitemid 33078202)
47. Tong GM, Rajah TT and Pento JT: The differential influence of EGF, IGF-I and TGF-beta on the invasiveness of human breast cancer cells. In Vitro Cell Dev Biol Anim 36: 493-494, 2000.
48. de Blaquiere GE, May FE and Westley BR: Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration. Endocr Relat Cancer 16: 635-647, 2009.
49. Lester BR and McCarthy JB: Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 11: 31-44, 1992.
50. Yamaguchi H, Pixley F and Condeelis J: Invadopodia and podosomes in tumor invasion. Eur J Cell Biol 85: 213-218, 2005.
51. Zigmond SH: Signal transduction and actin filament organization. Curr Opin Cell Biol 8: 66-73, 1996.
52. Schoenwaelder SM and Burridge K: Bidirectional signaling between the cytosckeleton and integrins. Curr Opin Cell Biol 11: 274-286, 1999.
53. DePasquale JA: Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF7 breast carcinoma cells. Histochem Cell Biol 112: 341-350, 1999.
54. Bryce NS, Clark ES, Leysath JL, Currie JD, Webb DJ and Weaver AM: Cortactin promotes cell motility by enhancing lamellipodial persistence. Curr Biol 15: 1276-1285, 2005. (Pubitemid 41026593)
55. Wang W, Liu Y and Liao K: Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. BMC Cell Biol 13: 12-49, 2011.
56. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ and Gil-Henn H: An EGFR-Src-Arg-Cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 71: 1730-1741, 2011.
57. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM and Mueller SC: Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034-3043, 2006.
58. Small JV and Resch GP: The comings and goings of actin: coupling protrusion and retraction in cell motility. Curr Opin Cell Biol 17: 517-523, 2005. (Pubitemid 41267166)
59. Liu X and Feng R: Inhibition of epithelial to mesenchymal transition in metastatic breast carcinoma cells by c-Src suppression. Acta Biochim Biophys Sin (Shanghai) 42: 496-501, 2010.
60. Helwani FM, Kovacs EM, Paterson AD, Verma S, Ali RG, Fanning AS, Weed SA and Yap AS: Cortactin is necessary for E-cadherin-mediated contact formation and actin reorganization. J Cell Biol 164: 899-910, 2004. (Pubitemid 38366901)
61. Zhang K, Wang D and Song J: Cortactin is involved in tranforming growth factor-beta1-induced epithelial-mesenchymal transition in AML-12 cells. Acta Biochim Biophys Sin (Shanghai) 41: 839-845, 2009.